cancidas and Hemolysis

cancidas has been researched along with Hemolysis* in 4 studies

Other Studies

4 other study(ies) available for cancidas and Hemolysis

ArticleYear
N,N'-diaryl-bishydrazones in a biphenyl platform: Broad spectrum antifungal agents.
    European journal of medicinal chemistry, 2019, Feb-15, Volume: 164

    N,N'-Diaryl-bishydrazones of [1,1'-biphenyl]-3,4'-dicarboxaldehyde, [1,1'-biphenyl]-4,4'-dicarboxaldehyde, and 4,4'-bisacetyl-1,1-biphenyl exhibited excellent antifungal activity against a broad spectrum of filamentous and non-filamentous fungi. These N,N'-diaryl-bishydrazones displayed no antibacterial activity in contrast to previously reported N,N'-diamidino-bishydrazones and N-amidino-N'-aryl-bishydrazones. The leading candidate, 4,4'-bis((E)-1-(2-(4-fluorophenyl)hydrazono)ethyl)-1,1'-biphenyl, displayed less hemolysis of murine red blood cells at concentrations at or below that of a control antifungal agent (voriconazole), was fungistatic in a time-kill study, and possessed no mammalian cytotoxicity and no toxicity with respect to hERG inhibition.

    Topics: Animals; Antifungal Agents; Biphenyl Compounds; Drug-Related Side Effects and Adverse Reactions; Erythrocytes; Fungicides, Industrial; Hemolysis; Hydrazones; Mice

2019
Alkylated Piperazines and Piperazine-Azole Hybrids as Antifungal Agents.
    Journal of medicinal chemistry, 2018, 01-11, Volume: 61, Issue:1

    The extensive use of fluconazole (FLC) and other azole drugs has caused the emergence and rise of azole-resistant fungi. The fungistatic nature of FLC in combination with toxicity concerns have resulted in an increased demand for new azole antifungal agents. Herein, we report the synthesis and antifungal activity of novel alkylated piperazines and alkylated piperazine-azole hybrids, their time-kill studies, their hemolytic activity against murine erythrocytes, as well as their cytotoxicity against mammalian cells. Many of these molecules exhibited broad-spectrum activity against all tested fungal strains, with excellent minimum inhibitory concentration (MIC) values against non-albicans Candida and Aspergillus strains. The most promising compounds were found to be less hemolytic than the FDA-approved antifungal agent voriconazole (VOR). Finally, we demonstrate that the synthetic alkylated piperazine-azole hybrids do not function by fungal membrane disruption, but instead by disruption of the ergosterol biosynthetic pathway via inhibition of the 14α-demethylase enzyme present in fungal cells.

    Topics: 14-alpha Demethylase Inhibitors; Alkylation; Animals; Antifungal Agents; Aspergillus; Azoles; Candida albicans; Cell Line; Hemolysis; Humans; Mice; Microbial Sensitivity Tests; Molecular Docking Simulation; Piperazines; Protein Conformation; Sterol 14-Demethylase

2018
Novel fluconazole derivatives with promising antifungal activity.
    Bioorganic & medicinal chemistry, 2018, 02-01, Volume: 26, Issue:3

    The fungistatic nature and toxicity concern associated with the azole drugs currently on the market have resulted in an increased demand for new azole antifungal agents for which these problematic characteristics do not exist. The extensive use of azoles has resulted in fungal strains capable of resisting the action of these drugs. Herein, we report the synthesis and antifungal activity of novel fluconazole (FLC) analogues with alkyl-, aryl-, cycloalkyl-, and dialkyl-amino substituents. We evaluated their antifungal activity by MIC determination and time-kill assay as well as their safety profile by hemolytic activity against murine erythrocytes as well as cytotoxicity against mammalian cells. The best compounds from our study exhibited broad-spectrum activity against most of the fungal strains tested, with excellent MIC values against a number of clinical isolates. The most promising compounds were found to be less hemolytic than the least hemolytic FDA-approved azole antifungal agent voriconazole (VOR). Finally, we demonstrated that the synthetic alkyl-amino FLC analogues displayed chain-dependent fungal membrane disruption as well as inhibition of ergosterol biosynthesis as possible mechanisms of action.

    Topics: Animals; Antifungal Agents; Candida; Cell Line; Cell Survival; Drug Design; Erythrocytes; Fluconazole; Fungi; Hemolysis; Mice; Microbial Sensitivity Tests; Structure-Activity Relationship; Voriconazole

2018
Novel alkylated azoles as potent antifungals.
    European journal of medicinal chemistry, 2017, Jun-16, Volume: 133

    Fluconazole (FLC) is the drug of choice when it comes to treat fungal infections such as invasive candidiasis in humans. However, the widespread use of FLC has resulted in the development of resistance to this drug in various fungal strains and, simultaneously has occasioned the need for new antifungal agents. Herein, we report the synthesis of 27 new FLC derivatives along with their antifungal activity against a panel of 13 clinically relevant fungal strains. We also explore their toxicity against mammalian cells, their hemolytic activity, as well as their mechanism of action. Overall, many of our FLC derivatives exhibited broad-spectrum antifungal activity and all compounds displayed an MIC value of <0.03 μg/mL against at least one of the fungal strains tested. We also found them to be less hemolytic and less cytotoxic to mammalian cells than the FDA approved antifungal agent amphotericin B. Finally, we demonstrated with our best derivative that the mechanism of action of our compounds is the inhibition of the sterol 14α-demethylase enzyme involved in ergosterol biosynthesis.

    Topics: Alkylation; Animals; Antifungal Agents; Azoles; Candida albicans; Candidiasis; Cell Line; Ergosterol; Fungi; Hemolysis; Humans; Mice; Microbial Sensitivity Tests; Mycoses

2017